Pharmacologic resistance in colorectal cancer: A review

William A. Hammond; Abhisek Swaika; Kabir Mody

doi:10.1177/1758834015614530

Pharmacologic resistance in colorectal cancer: A review

William A. Hammond, Abhisek Swaika, Kabir Mody

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Review article › peer-review

205 Scopus citations

Abstract

Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.

Original language	English (US)
Pages (from-to)	57-84
Number of pages	28
Journal	Therapeutic Advances in Medical Oncology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1177/1758834015614530
State	Published - Jan 2016

Keywords

Colon adenocarcinoma
Colon cancer
Resistance

ASJC Scopus subject areas

Oncology

Access to Document

10.1177/1758834015614530

Cite this

@article{86b6ab7b50ca4079961c24fc72f92a7b,

title = "Pharmacologic resistance in colorectal cancer: A review",

abstract = "Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.",

keywords = "Colon adenocarcinoma, Colon cancer, Resistance",

author = "Hammond, {William A.} and Abhisek Swaika and Kabir Mody",

year = "2016",

month = jan,

doi = "10.1177/1758834015614530",

language = "English (US)",

volume = "8",

pages = "57--84",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

number = "1",

}

TY - JOUR

T1 - Pharmacologic resistance in colorectal cancer

T2 - A review

AU - Hammond, William A.

AU - Swaika, Abhisek

AU - Mody, Kabir

PY - 2016/1

Y1 - 2016/1

N2 - Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.

AB - Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.

KW - Colon adenocarcinoma

KW - Colon cancer

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=84951827874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951827874&partnerID=8YFLogxK

U2 - 10.1177/1758834015614530

DO - 10.1177/1758834015614530

M3 - Review article

AN - SCOPUS:84951827874

SN - 1758-8340

VL - 8

SP - 57

EP - 84

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

IS - 1

ER -

Pharmacologic resistance in colorectal cancer: A review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this